Lannett Eyes Insulins Opportunity And Advances Respiratory Assets
CEO Tim Crew Sets Out Expectations For Pipeline As Firm Licenses Insulin Pen Patent
• By David Wallace
Insulin glargine and insulin aspart are two of Lannett’s major pipeline assets • Source: Shutterstock 
